-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Skin Cancer
New Cancer Drugs Often Bestow Little Benefit Regarding Survival or Wellbeing? (NHS Choices / BMJ)
Summary A quotation from the authors’ abstract may say it all: “This systematic evaluation of oncology approvals by the European Medicines Agency (EMA) in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality … Continue reading
Posted in Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), In the News, International, Management of Condition, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Statistics, Systematic Reviews, UK, Universal Interest
Tagged Advanced Melanoma: Improving Survival Rates, Assessment of Quality of Life, Bazian, Behind the Headlines, Better Regulation, Big Pharma, BMJ Publishing Group Ltd, British Medical Journal (BMJ), Cancer, Cancer Drugs Approved by EMA (2009-13), Cancer Drugs Approved on Basis of Surrogate End Points, Cancer Drugs Fund (CDF), Cancer Pharmaceuticals (New Approvals), Cancer Research, Cancer Survival, Cancer Survival Group: London School of Hygiene and Tropical Medicine, Cancer Treatment (Newer Drugs), Combination Nivolumab Plus Ipilimumab, Department of Global Health and Social Medicine: King's College London, Department of Health Policy: London School of Economics and Political Science, Department of Health Services Research and Policy: London School of Hygiene and Tropical Medicine, Drug Regulation, EMA: European Medicines Agency, European Medicines Agency, European Medicines Agency (Cancer Drug Approvals), European Medicines Agency (EMA), European Public Assessment Reports (EPARs), European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), European Society for Medical Oncology's Magnitude of Clinical Benefit Scale (MCBS), Evidence Versus Mythology, Faculty of Pharmacy: Riga Stradins University, Institute of Cancer Policy: King's College London, Kings College London, Latvia, London, London School of Economics and Political Science, London School of Hygiene and Tropical Medicine, London School of Hygiene and Tropical Medicine (LSHTM), LSE Health: London School of Economics and Political Science, LSHTM: London School of Hygiene and Tropical Medicine, Market Approval (New Cancer Drugs), Myth-Busting, Myths and Misconceptions About New Cancer Drugs, New Cancer Drug Approvals (EMA), Pharmaceutical Industry, Pharmaceutical Regulators, Pharmaceuticals, Quality of Life, Regulatory Experts, Regulatory Requirements, Regulatory Stringency, Regulatory System, Riga Stradins University (Latvia), Skin Cancer, Surrogate End Points Versus Subsequent Efficacy / Survival, Thinking Like a Patient and Acting Like a Taxpayer
Leave a comment
A Question of Height: a New Dimension in Statistical and Genetic Risk Factors? (BBC News / NHS Choices / British Journal of Psychiatry / NEJM)
Summary A number of studies point to the unexpected potential influence of physical height in the risks of developing various diseases (which may or may not be related). It was found last year that decreasing height is associated statistically with … Continue reading
Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Scotland, Statistics, UK, Universal Interest
Tagged Adult Height, Alzheimer Scotland Dementia Research Centre: University of Edinburgh, Atherosclerosis, Atherosclerosis (Hardening of the Arteries), Australia, BBC Health News, Behind the Headlines, British Heart Foundation, British Journal of Psychiatry, Cancer, Cancer Risk Factors, Centre for Cognitive Ageing and Cognitive Epidemiology: University of Edinburgh, Charles Perkins Centre and Exercise and Sport Sciences: University of Sydney, Coronary Artery Disease, Coronary Artery Disease (CAD), Coronary Heart Disease (CHD), Department of Epidemiology and Public Health (University College London), Division of Psychiatry: University of Edinburgh; Department of Epidemiology and Public Health: University College London, Epidemiology, Epidemiology and Statistics, ESPE: European Society for Paediatric Endocrinology, European Society for Paediatric Endocrinology Conference (2015), Genetic Risk Factors, Genetically Determined Height, Genetically Determined Height and Coronary Artery Disease, Health Survey for England, Health Survey for England (HSE), Height, Height and Cancer Risk, Height and Dementia Death, Karolinska Institute in Stockholm, Karolinska Institutet, Leducq Foundation, National Health Service (NHS) Scotland, National Institute for Health Research (NIHR), New England Journal of Medicine, Overlapping Risk Factors, Risk Factors, Risk of Coronary Artery Disease, Scottish Dementia Clinical Research Network, Scottish Health Survey, Short Stature and Dementia, Skin Cancer, Stature, Sweden, Sweden. Epidemiology, University College London, University of Cambridge, University of Edinburgh, University of Leicester, University of Sydney
Leave a comment
Malignant Melanoma: Increasing Incidence of Skin Cancer in the UK (BBC News / CRUK)
Summary It is estimated that 5,700 over-65s are diagnosed with malignant melanoma each year, compared to 600 in the mid-1970s. The over-65s were the first generation to “benefit” from cheaper foreign holidays and suntan salons. Risks of developing this condition … Continue reading
Posted in BBC News, Charitable Bodies, In the News, Practical Advice, Quick Insights, Statistics, UK, Universal Interest
Tagged ABCDE Checklist, Advanced Melanoma: Improving Survival Rates, Aix-Marseille University, Arm Mole Count: Skin Cancer Risk, Awareness and Campaigns, Awareness and Understanding, Awareness Raising, Baby-Boomer Generation, BBC Health News, Bristol-Myers Squibb, British Association of Dermatologists (BAD), Cancer Research UK, Cancer Research UK (CRUK), Combination Immunotherapy, Combination Nivolumab Plus Ipilimumab, Cross Cancer Institute (Canada) Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, CRUK: Cancer Research UK, CTLA-4, Dana-Farber Cancer Institute (Boston), Department of Medical Oncology: Royal Marsden Hospital, Drug Side-Effects, Epidemiology, Epidemiology and Statistics, European Cancer Congress (2016), European Institute of Oncology, European Society for Medical Oncology, Gill Nuttall: Melanoma UK, Hôpital de La Timone, Healthy Lifestyles, Hospital General Universitario Gregorio Marañón (Madrid), Immunotherapy, Immunotherapy Drugs, Incidence of Malignant Melanoma, Ipilimumab, Istituto Nazionale Tumori Fondazione Pascale, Lifestyle, Lifestyle Advice, Lifestyle Factors, Lifestyle Risk Factors, Malignant Melanoma, Melanoma Institute Australia, Memorial Sloan Kettering Cancer Center, Merck, Netherlands Cancer Institute, New England Journal of Medicine, Nivolumab, Odense University Hospital, Package Holiday Boom, PD-1, Pembrolizumab, Peter MacCallum Cancer Centre and University of Melbourne, Prof Carole Longson: National Institute for Health and Care Excellence (NICE), Public Health, Risk Factors for Malignant Melanoma, Royal Marsden Hospital, Sammons Cancer Center (Dallas); University of Michigan, Singleton Hospital (Swansea), Skin Cancer, Skin Cancer Statistics, Smilow Cancer Hospital of the Yale-New Haven Hospital, South West Wales Cancer Institute, Sunburn, Tasman Oncology Research: Southport Gold Coast, Unhealthy Lifestyles, United Kingdom and Ireland Association of Cancer Registries, University Hospital of Siena, University of Colorado, University of Essen, University of Sydney, University of Utah, University of Zürich Hospital, Unresectable Stage III or IV Melanoma, Untreated Melanoma, Veneto Region Oncology Research Institute, Weill Cornell Medical College, Yale Cancer Center, Yale University School of Medicine
Leave a comment
